What Stomorgyl Treats: Main Uses and Benefits

Treating Advanced Periodontal Disease and Systemic Oral Infections

The therapeutic role of this medication is considered relevant for the systemic management of advanced periodontal disease and severe oral infections in dogs and cats, particularly those conditions characterized by periods of heightened symptoms. It is applied where additional symptomatic support is needed to address conditions presenting with systemic or localized discomfort and heightened physiological activity. This treatment is relevant in conditions involving inflammatory or irritative processes such as established gingivitis, stomatitis, and pyorrhoea.

---

Symptomatic Relief and Clinical Context

This medication helps address symptom clusters that may become intense or disruptive, focusing on easing oral pain and pronounced inflammation of the oral lining. This symptomatic support contributes to improved comfort during periods of heightened symptoms. In situations where symptoms create noticeable functional strain, the treatment provides supportive relief associated with severe, persistent halitosis (foul breath), assisting with maintaining functional stability. The medicine plays a role in managing infections that may require additional management of discomfort, such as dental abscesses and fistulas. It often serves as an adjunct treatment to professional mechanical or surgical periodontal therapy.

---

Quick Fact: Relief for Inflammatory Symptoms

This medication is generally applied in settings where symptoms are associated with inflammatory or irritative states, focusing on easing oral pain, supporting relief from gum inflammation, and managing malodor symptoms.

Regulatory References

1. Israel Ministry of Health Product Information

The eligibility for Stomorgyl is strictly defined by its regulatory classification as a Veterinary Medicinal Product intended for use in the specified target species.

Eligibility Scope

Category	Official Regulatory Statement
Populations for whom use is allowed	Dogs and Cats (Target Species). The product is exclusively for animal treatment only.
Populations for whom use is contraindicated	Animals with a known hypersensitivity to the active substances, Spiramycin or Metronidazole [Source 1.2, 1.4].
Condition-specific restrictions	Contraindicated in animals with certain hepatic disorders [Source 3.1].

Restrictions and Special Considerations

• Pregnancy and Lactation: Use is not recommended during both pregnancy and lactation in dogs and cats [Source 1.2, 1.3]. The safety of the medicine has not been demonstrated in pregnant animals, and the active components are known to be excreted in milk.
• Other Comorbidities: Use requires caution and veterinary supervision in animals with severe diseases of the heart or kidneys [Source 2.2].
• Humans: The medicine is strictly not authorized for human use due to its veterinary classification [Source 1.6].

The interaction profile for this combination product is defined by the documented properties of its active ingredients, Metronidazole and Spiramycin, as stated in regulatory information.

Contraindicated and Inadvisable Combinations

The label formally restricts the use of certain co-administered substances. The combination with alcohol (including alcohol-containing preparations) is strictly inadvisable due to the risk of a severe disulfiram-like reaction. Similarly, co-administration with Disulfiram is inadvisable due to the documented risk of acute psychotic reactions. The Spiramycin component carries antagonism warnings, specifically advising against concurrent use with certain Bactericidal Antibiotics such as Penicillins and Cephalosporins, and other Macrolide Antibiotics.

Exposure-Altering Pharmacokinetic Effects

The Metronidazole component can inhibit the hepatic metabolism of several medicinal products. This action increases the plasma concentration of Oral Anticoagulants (Warfarin-type), raising the risk of bleeding, and also increases the serum levels of Phenytoin and Cyclosporine. Conversely, co-administration with Phenobarbital may accelerate the elimination of Metronidazole, potentially reducing its serum concentration. Furthermore, the Spiramycin component is documented to reduce the absorption of Carbidopa, which impacts the resulting levels of Levodopa.

Timing and Population Constraints

A mandatory timing requirement specifies that alcohol must be avoided during therapy and for at least 48 hours afterward. Regulatory notes also highlight that in cases of advanced hepatic insufficiency, Metronidazole clearance is substantially impaired, leading to the risk of drug accumulation.

The mechanism of Stomorgyl relies on the pharmacodynamic complementation of its two active components, each targeting an essential cellular process within the pathogenic microbes. This dual strategy addresses the simultaneous requirements for modulating polymicrobial populations.

Genetic Disruption of Anaerobic Pathogens

The mechanism of Metronidazole is activated when microbial nitroreductase enzymes in anaerobic bacteria and protozoa reduce its chemical structure in a low-oxygen environment. This creates highly reactive free radicals that cause immediate and irreversible DNA strand breakage and destruction. This action initiates a cidal effect, resulting in the rapid cessation of replication and cell viability, which consequently results in the attenuation of pathogen-driven inflammatory signaling in deep tissues.

Arresting Protein Synthesis in Susceptible Bacteria

The mechanism of Spiramycin is based on its ability to reversibly bind to the 50S ribosomal subunit of susceptible bacteria. This binding physically blocks the translocation step of peptide chain elongation, thereby halting the synthesis of essential proteins required for cell growth. This bacteriostatic effect stops the proliferation of the microbial population, resulting in the control of microbial population levels and creating a condition that is conducive to the host immune system clearing the non-replicating organisms.

The use of Stomorgyl (Spiramycin and Metronidazole) is based on weight-based parameters for administration in dogs and cats.

The medication is administered via the oral route as a film-coated tablet designed for swallowing. The standard schedule is once daily, with the total duration of the treatment course typically ranging from 5 to 10 days. The medication is typically administered for the full duration of the prescribed course.

---

Dosage Calculation and Administration Conditions

The dosing regimen is standardized to ensure the delivery of both active components based on the patient's body weight. The required dose is 12.5 mg of Metronidazole and 75,000 IU of Spiramycin per kilogram (kg) of body weight, administered once every 24 hours. The various strengths (Stomorgyl 2, 10, and 20) correspond to this ratio, with the tablet chosen based on the patient's mass (e.g., Stomorgyl 10 is intended for 10 kg increments).

A physical requirement for this formulation is that the tablets are not broken or crushed prior to administration. This ensures the integrity of the film-coated delivery system. Furthermore, the lowest strength, Stomorgyl 2, is noted as being used for cats due to their smaller size and weight.

Research Evidence: Overview of Studies for Stomorgyl

This section provides an overview of the types of research and observational studies that have been conducted for the combination of metronidazole and spiramycin. The focus here is on describing the study designs and what researchers monitored, while remaining neutral about the drug combination. Findings describe patterns observed in the studies and help contextualize how the drug combination was examined in controlled settings, but this research does not determine whether an individual will respond similarly.

---

Evidence for Use in Advanced Periodontal Disease and Complex Oral Infections

The combination therapy was studied for complex oral conditions, including severe gum diseases, gingivitis, periodontitis, and related oral infections such as dental fistulas.

Researchers examined the treatment in small cohorts of dogs with pre-existing periodontal disease using controlled experimental studies. These studies focused on outcomes linked to inflammatory or irritative states in the mouth and measured changes in specific bacterial populations within the dental plaque (biofilm). Laboratory studies explored the concept of synergy, or complementary action, between metronidazole and spiramycin. These findings indicate patterns related to the antimicrobial activity of the combined agents against the types of pathogens typically associated with these complex, polymicrobial infections.

Focus of Study Outcomes: Microbial Shifts and Mechanistic Evidence

Research specifically monitored the microbial profile, or the balance of bacterial species in the mouth, during the defined period of administration. Studies reported measurements showing changes in the composition of the oral microbiome during the brief treatment period, including shifts in bacteria like Porphyromonas. This evidence contributes to understanding microbiological patterns observed during the research period. The reported outcomes were primarily short-term and heavily focused on this microbiological impact, rather than on long-term disease progression.

---

The Role of Stomorgyl in Adjunct Therapy

The research has explored the combination’s use in a specific setting: as an adjunct treatment (an add-on therapy) alongside professional mechanical and surgical procedures for gum disease. This context is important because comparative evidence is lacking for the combination used alone against a placebo or another antibiotic class in large-scale studies. The results apply only to the populations studied—specifically, animals undergoing comprehensive dental care. The evidence, therefore, helps contextualize the drug combination within the research setting, but does not determine whether outcomes differ when the drug is used as a stand-alone therapy.

---

Duration of Observation and Long-Term Research

The typical length of observation and follow-up in the existing studies was limited, usually lasting only the length of the administration course, which is commonly less than 10 days. Research explored short-term symptom changes and the immediate microbiological response. This means that long-term effects are not fully established regarding sustained outcomes and changes observed in dental tissues months or years later. There is limited information for long-term outcomes on the durability of the microbiological shifts monitored in these studies.

---

Study Populations and Evidence in Defined Groups

The primary studies was observed in specific veterinary populations, mainly small cohorts of dogs that had been diagnosed with periodontal disease. The sample sizes were modest in the short-term controlled experimental studies, meaning the data primarily describes patterns in those specific, limited groups. Official summaries indicate that there is limited information regarding the use of this combination in pregnant animals.

---

What Is Still Uncertain and Key Research Limitations

Evidence quality varies across studies, and the overall certainty remains low for comprehensive, long-term clinical endpoints. Research highlights what is known—and what is still uncertain—about the broader consequences of observed microbiological shifts on long-term dental health. Key limitations include the fact that follow-up durations were limited, and the evidence focuses mainly on the microbiological changes rather than on large-scale, functional clinical outcomes. Comparative evidence is lacking in a standardized manner, and subgroup findings are uncertain due to the modest sample sizes.

Common questions about Stomorgyl (FAQ)

Q: Is it okay to take Stomorgyl with vitamins or supplements?

Official product information for the active ingredients generally indicates no known major interactions with common vitamins or herbal supplements. However, official guidance emphasizes the need to check any liquid remedies or preparations for alcohol content. This must be strictly avoided during therapy and for at least 48 hours afterward.

Q: Can Stomorgyl make you feel tired or dizzy?

Regulatory documents for the Metronidazole component list feeling sleepy (somnolence) or dizzy (vertigo) as possible side effects. These effects are typically described as rare in the product information. This possibility is described in the product information as is standard practice for medicines that may affect the central nervous system.

Q: What should I do if I accidentally miss a dose of Stomorgyl?

Official product information describes a procedure for missed administration. This procedure suggests taking the dose as soon as it is remembered, unless it is nearly time for the subsequent dose, in which case the procedure indicates skipping the missed dose. Official guidance addresses not administering a double quantity to compensate for a forgotten one.

Q: Does Stomorgyl affect birth control pills?

Official information for Metronidazole does not generally indicate that it reduces the effectiveness of hormonal birth control (pills, patches, or rings). If a person experiences severe diarrhea or vomiting while on this medication, reduced absorption could be a concern. Official information suggests that backup methods may be required in those specific situations.

Q: Is a metallic taste in the mouth common with Stomorgyl?

A sharp, unpleasant or metallic taste in the mouth is a common and well-known side effect associated with the Metronidazole component of the medicine. This is a documented sensory side effect in official safety information. This effect is typically observed to resolve after treatment completion.

Q: Can Stomorgyl cause yeast infections?

Regulatory information for antibacterial agents indicates that, as with many antibiotics, the components of Stomorgyl can alter the body’s normal microbial balance. This alteration can sometimes allow non-susceptible organisms, such as fungi, to overgrow. This potential shift in flora could be a condition leading to a secondary infection like a yeast infection.

Q: How is Stomorgyl eliminated from the body?

According to official regulatory documents, the Metronidazole component is processed primarily by the liver. The drug and its related substances are then largely eliminated from the body through the urinary system. The product label also notes that clearance may be impaired in cases of advanced hepatic insufficiency.

Q: Is it normal to feel nauseous when taking Stomorgyl?

Nausea, vomiting, and loss of appetite are common gastrointestinal effects frequently reported in association with the Metronidazole component. These are detailed in official safety information. If these effects become severe or persistent, regulatory advice notes the need for consulting a professional.

Q: Is Stomorgyl a prescription-only medicine?

Official sources classify Stomorgyl as a Veterinary Medicinal Product intended solely for animal use. This means it is restricted for animal use and, in most regulatory systems, is subject to veterinary prescription.

Q: Can Stomorgyl affect sleep patterns?

Official documents for the active ingredients sometimes list side effects related to the central nervous system (CNS), such as dizziness or confusion. These CNS effects could potentially influence sleep quality, although a direct, universal impact on sleep is not always explicitly listed in the product safety profile.

Q: Does Stomorgyl contain any common allergens?

Official product documentation provides a complete list of all excipients, or inactive ingredients, used in the tablet formulation. For individuals with known sensitivities, official guidance highlights the need for reviewing the full list of components against known allergies.

Q: Is Stomorgyl related to sulfa drugs?

Official classification confirms that Stomorgyl is a combination of Spiramycin (a macrolide) and Metronidazole (a nitro-5-imidazole derivative). Neither of these two active ingredients belongs to the sulfonamide, or 'sulfa drug,' class of antibiotics.

Storage and Disposal of Stomorgyl (Veterinary)

The storage and disposal of Stomorgyl film-coated tablets must adhere strictly to regulatory requirements to ensure stability and environmental protection.

---

Official Storage Conditions

Requirement	Condition
Temperature	Store below 25 C (Do not exceed)
Protection	Store in a dry place and protect from light
Packaging	Keep in the original container (outer carton)
Safety	Keep out of the sight and reach of children

---

Disposal Instructions

Disposal of unused or expired product must be executed in accordance with national requirements. Medicines must not be disposed of via wastewater or household trash. Consult a veterinary surgeon or pharmacist for proper disposal methods.